We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KCGI
151
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
$97.6K 0.02%
9,000
– –
LEXX icon
152
Lexaria Bioscience
LEXX
$8.71M
$96.7K 0.02%
1,775
+1,667
+1,544% +$63.7K
NXTC icon
153
NextCure
NXTC
$23.8M
$95.9K 0.02%
3,585
-1,450
-29% -$25K
BLCO icon
154
Bausch + Lomb
BLCO
$5.99B
$91.7K 0.02%
5,300
+1,800
+51% +$28K
AMLX icon
155
PUT
Amylyx Pharmaceuticals
AMLX
$2.54B
$90.3K 0.02%
31,800
– –
CGON icon
156
CG Oncology
CGON
$6.62B
$90K 0.02%
+2,050
New +$83.7K
MO icon
157
Altria Group
MO
$114B
$87.2K 0.02%
2,000
-4,000
-67% -$166K
MITK icon
158
Mitek Systems
MITK
$835M
$79K 0.02%
5,600
-2,000
-26% -$24.5K
NNAGU
159
DELISTED
99 Acquisition Group Inc Unit
NNAGU
$78.7K 0.02%
7,500
– –
AITRU
160
DELISTED
AI Transportation Acquisition Corp Unit
AITRU
$78.2K 0.02%
7,500
– –
IOVA icon
161
Iovance Biotherapeutics
IOVA
$2.83B
$74.1K 0.02%
5,000
– –
ACET icon
162
Adicet Bio
ACET
$74.7M
$73.4K 0.02%
+1,952
New +$80.8K
HHH icon
163
Howard Hughes
HHH
$4.03B
$72.6K 0.02%
1,049
-2,098
-67% -$156K
JSPR icon
164
Jasper Therapeutics
JSPR
$23.6M
$70.6K 0.02%
+2,406
New +$42.7K
RAPT
165
PUT
DELISTED
RAPT Therapeutics
RAPT
$67.3K 0.02%
938
– –
TGTX icon
166
TG Therapeutics
TGTX
$7.62B
$66.3K 0.02%
+4,361
New +$69.5K
ATXS
167
DELISTED
Astria Therapeutics
ATXS
$65.5K 0.01%
4,652
-186,599
-98% -$2.32M
FDMT icon
168
4D Molecular Therapeutics
FDMT
$562M
$63.7K 0.01%
+2,000
New +$51K
BHC icon
169
CALL
Bausch Health
BHC
$2.34B
$63.7K 0.01%
+6,000
New +$52.5K
GDX icon
170
VanEck Gold Miners ETF
GDX
$27.4B
$63.2K 0.01%
2,000
-1,000
-33% -$28.4K
LNTH icon
171
Lantheus
LNTH
$6.59B
$62.2K 0.01%
+1,000
New +$58.8K
EVO icon
172
Evotec
EVO
$711M
$60.3K 0.01%
+7,700
New +$60.6K
KSS icon
173
Kohl's
KSS
$2.19B
$58.3K 0.01%
2,000
– –
IRON icon
174
Disc Medicine
IRON
$2.97B
$55.8K 0.01%
+896
New +$58.1K
KRYS icon
175
Krystal Biotech
KRYS
$9.66B
$53.4K 0.01%
+300
New +$41.7K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.